Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 5;119(8):1632-1635.
doi: 10.14309/ajg.0000000000002761. Online ahead of print.

Effectiveness of Tofacitinib in Patients With Ulcerative Colitis: A Nationwide Veterans Administration Cohort Study

Nabeel Khan  1   2 , Ramaswamy Sundararajan  1 , Manthankumar Patel  1 , Chinmay Trivedi  1 , Yu-Xiao Yang  1   2   3
Affiliations

Effectiveness of Tofacitinib in Patients With Ulcerative Colitis: A Nationwide Veterans Administration Cohort Study

Nabeel Khan et al. Am J Gastroenterol. .

Abstract

Introduction: There is paucity of data on the effectiveness and safety of tofacitinib among elderly patients with ulcerative colitis (UC).

Methods: Through a retrospective cohort study among the US National Veterans Affairs Healthcare System, we evaluated effectiveness among the elderly (≥65) and young (<65) patients with UC initiated on tofacitinib.

Results: Among 158 patients (53 elderly, 105 young), effectiveness at 12 months was 50.94% in the elderly and 33.33% in the young ( P = 0.032).

Discussion: In a nationwide cohort of patients with UC initiating tofacitinib, effectiveness was seen in half of the elderly patients.

PubMed Disclaimer

Conflict of interest statement

Guarantor of the article: Nabeel Khan, MD.

Specific author contributions: N.K. has participated in study supervision, study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. R.S. has participated in study concept and design, acquisition of data, interpretation of data, and drafting of the manuscript. M.P. has participated in study concept and design, acquisition of data, interpretation of data, and drafting of the manuscript. C.T. has participated in acquisition of data and drafting of manuscript. Y.-X.Y. has participated in study concept and design, acquisition of data, formal statistical analysis, data visualization, analysis and interpretation of data, and critical revision of the manuscript. All the authors have reviewed and approved the final version of this article.

Funding support: This study was supported by an unrestricted research grant from Pfizer. Pfizer had no role in the study concept and design, acquisition of data, analysis and interpretation of data, or preparation of the manuscript.

Potential competing interests: N.K. has received an unrestricted research grant from Pfizer, Luitpold, and Takeda Pharmaceuticals as well as Samsung BioEpis. He has served on Advisory Board of Pharmacosmos. Y.-X.Y. received funding from AbbVie to support investigator-initiated research. The remaining authors have nothing to disclose regarding conflicts of interest.

Data availability statement: The data for this manuscript cannot be made available in accordance with the HIPAA rules. However, de-identified data (without patient name and SSN) can be made available upon reasonable request.

References

    1. Danese S, Grisham M, Hodge J, et al. . JAK inhibition using tofacitinib for inflammatory bowel disease treatment: A hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 2016;310(3):G155–62. - PMC - PubMed
    1. Sandborn WJ, Su C, Sands BE, et al. ; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376(18):1723–36. - PubMed
    1. Ha C, Ullman TA, Siegel CA, et al. . Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 2012;10(9):1002–7; quiz e78. - PubMed
    1. Nguyen GC, Sheng L, Benchimol EI. Health care utilization in elderly onset inflammatory bowel disease: A population-based study. Inflamm Bowel Dis 2015;21(4):777–82. - PubMed
    1. Jeuring SF, van den Heuvel TR, Zeegers MP, et al. . Epidemiology and long-term outcome of inflammatory bowel disease diagnosed at elderly age-an increasing distinct entity? Inflamm Bowel Dis 2016;22(6):1425–34. - PubMed

Grants and funding

LinkOut - more resources